Tolvaptan for the treatment of the syndrome of inappropriate antidiuresis (SIAD)
Tolvaptan for the treatment of the syndrome of inappropriate antidiuresis (SIAD)
About this item
Full title
Author / Creator
Publisher
London, England: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
London, England: SAGE Publications
Subjects
More information
Scope and Contents
Contents
The syndrome of inappropriate antidiuresis (SIAD), the commonest cause of hyponatraemia, is associated with significant morbidity and mortality. Tolvaptan, an oral vasopressin V2-receptor antagonist, leads through aquaresis to an increase in serum sodium concentration and is the only medication licenced in Europe for the treatment of euvolaemic hyp...
Alternative Titles
Full title
Tolvaptan for the treatment of the syndrome of inappropriate antidiuresis (SIAD)
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_383547ac4d0248dc8524e6fcc7c23a62
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_383547ac4d0248dc8524e6fcc7c23a62
Other Identifiers
ISSN
2042-0188
E-ISSN
2042-0196
DOI
10.1177/20420188231173327
